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Summary We evaluated the MDR1 expression levels in 77 osteosarcomas and investigated whether MDR1
mRNA expression in osteosarcomas varies with location within the tumour, following chemotherapy, or after
metastasis. We modified the semiquantitative reverse transcription-polymerase chain reaction (RT-PCR)
assay to determine accurately the levels of MDR1 mRNA expression in clinical specimens. We show that
specimens collected from multiple locations in six tumours revealed very little variation in MDR1 expression
suggesting that the levels ofMDR1 in these tumours do not vary greatly with location within the tumour mass.
In a comparison of pre and post-chemotherapy specimens it was found that MDR1 levels did not change
appreciably following chemotherapy in 16 of 20 cases. In addition, in eight of ten specimens obtained before
and after metastasis, the amount of MDR1 mRNA was found to remain relatively constant despite metastatic
spread. Thus, many osteosarcomas exhibited intrinsic expression of MDRI mRNA before multidrug regimens
which invariably included doxorubicin and, in most cases, MDR1 expression was not induced following
chemotherapeutic treatment. Our results suggest that some osteosarcoma patients may have primary tumours
which are resistant to doxorubicin. These individuals may benefit from different chemotherapeutic regimens,
e.g. the addition of MDR reversal agents.
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heterogeneity; tumour progression
In vitro, the multidrug resistance phenotype is mediated by
the expression of several genes, one of which is the 170 kDa
P-glycoprotein efflux pump, which acts to decrease intracel-
lular concentration of drugs. P-glycoprotein is encoded by the
MDR] gene in humans and transfection of MDR1 cDNA
confers resistance to a wide spectrum of anti-cancer drugs in
vitro, including vinca alkaloids and anthracyclins (reviewed in
Endicott and Ling, 1989; Borst, 1991; Gottesman and Pastan,
1993). P-glycoprotein/MDRI expression is likely to be
involved in the resistance of certain types of tumours,
particularly leukaemias (Marie et al., 1993; Campos et al.,
1992) and lymphomas (Miller et al., 1991), to chemotherapy.
Although the role of MDR1 in most solid tumours remains
controversial, a correlation of P-glycoprotein expression and
outcome has been demonstrated for some childhood cancers
(Chen et al., 1991, 1990). In addition, in a pilot study of
osteosarcoma, we found that patients whose tumours
expressed high levels of MDR1 mRNA tended to have a
worse prognosis than those patients with low levels of
tumour MDR1 expression (Wunder et al., 1993). Doxor-
ubicin, a drug involved in the MDR phenotype, is highly
effective in the treatment of this disease and is included in all
osteosarcoma chemotherapy protocols. Relapse in osteosar-
coma patients could relate to the development of resistance to
doxorubicin (Bell et al., 1990).
Numerous studies have described the detection of MDR1
or P-glycoprotein in a variety of cancers (Chan et al., 1990;
Wunder et al., 1993; Goldstein et al., 1989; Holzmayer et al.,
1992); however, methods traditionally used to measure levels
of MDR1/P-glycoprotein expression in tumours demon-
strated definite limitations. RNA hybridisation assays and
immunohistochemistry are useful in detecting MDR1/P-
glycoprotein overexpression but lack sensitivity to detect the
lower levels of MDR1 expression known to confer drug
resistance in cell lines (Shen et al., 1986). Furthermore, there
is evidence to suggest that low levels of expression may be
clinically significant in tumours (Vergier et al., 1993). In the
present study we describe a refined RT-PCR assay capable
of sensitive detection and quantitation of low-level MDR1
expression in tumour specimens. We have used this assay to
address the question of whether MDR1 expression varies
with location within the tumour by determining the level of
MDR1 mRNA expression in multiple specimens collected
from different sites of the same primary tumour. It has been
shown that MDR1 expression may be induced in cell lines
following transient exposure to chemotherapeutic agents
(Chaudhary and Roninson, 1993). To investigate whether
MDR1 levels in osteosarcoma specimens could be increased
by chemotherapy, we analysed specimens collected from
tumours both before and after chemotherapy. We also
investigated whether MDR1 expression changes with pro-
gression by analysing specimens from biopsy through
recurrence with metastasis.
Materials and methods
Cell lines and tumour specimens
KB3-1 parental drug-sensitive and KB8 and KB8-5 drug-
resistance carcinoma cell lines were obtained from MM
Gottesman (Akiyama et al., 1985). KB8 represents the first
step in selection from KB3-1 cells and exhibits 2-fold
resistance to colchicine and a 6- to 10-fold increase in
MDR1 mRNA. KB8-5 cells have 40-fold increased expres-
sion of MDR1 without gene amplification and are four times
more resistant to colchicine than KB3-1 cells.
All osteosarcoma specimens were obtained from patients
who presented free of metastatic disease. All patients received
neoadjuvant chemotherapy using protocols that included
doxorubicin. When possible, specimens were collected at
both biopsy and resection, as well as from various locations
within the tumour. Specimens were also collected from lung
metastasis in the event of recurrent systemic disease.
Specimens were obtained immediately after removal and
flash-frozen in liquid nitrogen.
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Specimens were pulverised while frozen and total RNA was
extracted by a standard guanidinium thiocyanate-caesium
chloride gradient procedure (Sambrook et al., 1989). Small
specimens (< 100 mg) were extracted by the acid guanidi-
nium-phenol procedure (Chomczynski and Sacchi, 1987).
Test extractions using both techniques on the same specimen
yielded similar quality RNA and consistent PCR results (data
not shown). The RNA yield was measured by the orcinol
reaction (Lin and Schjeide, 1969).
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could be quantitated for the KB8 cell line which represents
the first step in the step-wise selection for drug resistance in
vitro. The KB cell lines were included in each of the
subsequent experiments and tumour MDR1 mRNA levels
were normalised to the KB8 cell line within each RT-PCR
assay. In 51 separate experiments the ratio of MDR1 mRNA
to the internal control PBGD mRNA for KB8 cells was
0.40+0.07 indicating that the technique was reproducible. In
addition, different preparations of KB8 mRNA gave similar
results.
Analysis of MDR] mRNA expression in primary human
Quantitative RT-PCR osteosarcomas
The quantitative RT-PCR assay was a modification of the
semi-quantitative assay developed by Noonan et al. (1990).
cDNA was synthesised using 200 ng total cellular RNA in
8 ,l of reverse transcriptase (RT) reaction solution. RT
activity was denatured by incubation at 94°C for 5 min. PCR
was performed using 4 ,l of the denatured cDNA reaction
(100 ng) in a total 12 jul reaction volume containing 1 mM
magnesium chloride, 10 mM Tris-HCl (pH 8.3), 50 mM
potassium chloride, 0.01% gelatin, 0.2 units AmpliTaq
Polymerase (Perkin-Elmer/Cetus) and 22.5 pmol of each
primer. Parameters for amplification were an initial 4 min
denaturation at 94°C, followed by 25 to 31 cycles of 30 s at
94°C, 30 s at 55°C, 1 min at 72°C (Thermocycler, Perkin-
Elmer/Cetus). Primers specific for MDR1 were those
described in Noonan et al. (1990) and generated at 167 bp
product. These were co-amplified with porphobilinogen
deaminase (PBGD)-specific primers 5'-TGTCTGGTAACG-
GCAATGCG-3' (sense strand, exon 1) and 5'TTGCCAC-
CACACTGTCCGTCT-3' (antisense strand, exon 3) which
generated a 121 bp product (Finke et al., 1993). PBGD
served as an internal control for the quality and amount of
template in each reaction. The MDR1 and PBGD primers
were initially tested in separate reactions. Using the two sets
of primers together in the same reaction did not alter the
kinetics of amplification and therefore the products were co-
amplified. The PCR products were separated by 12%
polyacylamide gel electrophoresis (PAGE), stained with
ethidium bromide, photographed with positive/negative film
(Polaroid) and the band intensities were quantitated by laser
densitometry (Molecular Dynamics 300A computing Densit-
ometer) from the negatives. For each sample, reactions were
performed over a range of cycles (generally 25-31) which
included the logarithmic phase of the PCR. Only values in
the logarithmic phase (typically 25 to 27 cycles for 100 ng of
cDNA) were used to quantitate the levels of mRNA
expression. Each sample was assayed at least twice. The
ratio of MDR1 mRNA was calculated relative to that of
PBGD mRNA in each reaction. A reaction using KB8 RNA
was included in each RT-PCR as a kinetic control. KB8 was
also used as a standard of low level of functional expression
against which tumour MDR1 expression was normalised.
Results
Quantitative assay for MDR] mRNA expression
The semiquantitative RT-PCR assay of Noonan et al. (1990)
was modified to quantitate the levels of MDR1 mRNA
observed in osteosarcomas. Expression of the PBGD mRNA
was used as an internal control owing to its low level of
expression, and since it has been found to lack pseudogenes
(Chretien et al., 1998). A series of multidrug-resistant cell
lines selected from KB3-1-sensitive cells were used to optimise
the assay conditions and were subsequently used as controls
in each experiment. Kinetic analysis of RT-PCR with the
KB cell line RNAs using PBGD as an internal control gene is
shown in Figure 1. The KB8 cell line exhibited coincidence of
the logarithmic phase of amplification of PBGD-specific
product over a similar range of cycles as MDR1-specific
product. Thus, the low level of expression of MDR1 mRNA
The level of expression of MDR1 mRNA was evaluated as
shown in Figure 2 in 77 primary osteosarcomas and found to
vary extensively among the different specimens (Figure 3).
Approximately 30% of specimens exhibited MDR1 mRNA
KB3-1 KB8 KB8-5
MDR1
PBGD
Figure 1 Kinetic analysis of RT-PCR from 25-31 cycles using
PBGD as an internal control in KB3-1 drug-sensitive parental
cells and KB8 and KB8-5 drug-resistant cell lines.
1.14 0.85 4.3 3.5 Level relative
to KB8 cells
Figure 2 Levels of MDR1 expression in four primary
osteosarcoma specimens (tumours 408-1, 424-1, 428-1 and 429-
1). Levels of MDR1 and internal control PBGD mRNAs were
assayed by RT-PCR analysis over four cycles (25-31 cycles).
Levels were determined from the logarithmic phase of the RT-
PCR for each sample and values were calculated relative to the
levels exhibited by KB8 drug-resistant cells as described in
Materials and methods.
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Figure 3 Distribution of MDR1 mRNA levels in primary
osteosarcoma specimens. Levels were determined by RT-PCR
and calculated relative to KB8 cells as described in Materials and
methods.MDR1 gene expression in osteosarcoma
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levels less than that of KB8. These amounts would be
undetectable or only semi-quantitative by the previous assays.
Many of the osteosarcoma specimens expressed moderate
levels of MDR1, greater than twice that of KB8 cells.
Furthermore, some tumours had very high levels of
expression (Figure 3), in the range of KB8-5 cells which
represent the second step in MDR selection.
MDR] mRNA levels in different locations within the same
tumour
To investigate whether tumour heterogeneity would have a
major effect on determination of the MDR1 mRNA levels in
the specimens, samples were collected from multiple locations
within the primary tumour in six cases. In all cases MDR1
levels (Table I) were found to be relatively constant from one
location to the next as shown for two cases in Figure 4.
Comparison of MDR] mRNA levels before and after
neoadjuvant chemotherapy
For 20 cases, biopsy and resection specimens were collected
before and after the administration of neoadjuvant che-
motherapy, which included doxorubicin. The levels of
expression found before and after administration of
Table I MDR1 expression in specimens obtained from different
geographic sites of each tumour
Case Site la Site 2a Site 3a
190 0.76 0.98 0.98
315 3 3.6 5.2
424 0.78 0.75
306 5.3 4
308 16.1 11.25
305 0.65 0.54
aLevels relative to KB8.
Case 424
Sitcf 1 Site 2
MDR1
PBGD
0.75 0.78
Case 306
Site 1
Level relative
to KB8 cells
chemotherapy were compared using a paired t-test. There
was no significant difference found between the two groups,
although there was a trend detected towards somewhat
increased levels of expression following drug treatment (mean
difference between the two groups was 0.5, P=0.07). Most of
the difference in the two groups could be attributed to four
cases in which the level of expression increased substantially
(see Figure 5). The increases in expression in these four cases
were 0.6 to 2.6 (case 6), 1.1 to 2.4 (case 10), 1.3 to 3.5 (case
12) and 2.8 to 7.3 (case 19). In the remaining 16 cases, seven
showed somewhat higher levels of expression after che-
motherapy and nine showed somewhat lower levels after drug
treatment. None of the cases demonstrating a lower
expression after chemotherapy fell more than 50% of the
pretreatment level.
Evaluation of MDRI mRNA levels in metastatic lesions
Specimens were obtained before and after metastasis for ten
osteosarcoma patients. As indicated in Table II, biopsy and
resection specimens, as well as lung metastases, were found to
exhibit a consistent level of MDR1 mRNA throughout
progression in the majority of cases. Two cases (cases 4 and
23) did show an increase in MDR1 mRNA in the metastatic
specimens.
Discussion
The reliable detection and quantitation of MDR1 expression
continues to be an issue in clinical investigations. Low levels
of MDR1 expression are seen to confer drug resistance in
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Figure 5 Comparison of MDR1 expression in biopsy (LI) and
resection (0) specimens. Levels were determined by RT-PCR
and calculated relative to KB8 cells as described in Materials and
methods. Site 2
5.3
MDR1
PBGD
Level relative
4.0 to KB8 cells
Figure 4 Levels of MDR1 mRNA expression for tumours 424
and 306 at two geographic locations within the same tumour
(sites 1 and 2). Levels of MDR1 and internal control PBGD
mRNAs were by RT-PCR analysis over four cycles (25-31
cycles). Levels were determined from the logarithmic phase of the
RT-PCR for each sample and values were calculated relative to
the levels exhibited by KB8 cells as described in Materials and
methods.
Table II Relative MDR1 mRNA levels in consecutive specimens
from ten individuals
Case Biopsy Resection First metastasis Second metastasis
7 0.65 0.54 0.54
4 0.45 0.88 2.71 1.44
11 1.15 1.03 0.62 1.2
15 1.57 0.96 1.16
21 NS 0.65 1.05
22 1.96 NS 2.34
23 0.54 NS 1.1 1.84
20 3.68 3.5 3.1
24 NS 1.24 0.76
5 0.6 0.33 0.9
NS, no specimen.MDR1 gene expression in osteosarcoma
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vitro and may have significance clinically. However, such
levels remain undetectable by immunohistochemistry and
were only detectable semi-quantitatively by previous RT-PCR
assays (Noonan et al., 1990). The issues of sensitivity (Kandel
et al., 1995) as well as specificity of the antibodies (Rao et al.,
1994) remain a major concern in the interpretation of these
studies. Previous investigations in our laboratory have shown
that commercially available antibodies to P-glycoprotein fail
to allow reliable detection of protein in drug-resistant cell
lines expressing at levels lower than KB8-5 (Kandel et al.,
1995). This method of detection, therefore, is not sufficiently
sensitive to detect gene expression in the majority of clinical
osteosarcoma specimens which express the gene in lower
levels more similar to KB8 cells. In this study we have
demonstrated that RT-PCR is a highly reproducible and
sensitive method to detect MDR1 expression at low to
moderate levels as exhibited by KB8 cells. The KB8 cell line
represents the first step in selection for resistance to drug with
an approximately 10-fold increase over the parental line in
the amount of MDR1 mRNA and may be analogous to the
earliest stage in the development of resistance from drug-
sensitive cells in tumours. PBGD was selected as an
appropriate control gene for the current investigations since
the low level of expression of this gene was similar to MDR1
expression in KB8 cells, which approximated levels of
expression for most of the clinical specimens. Kinetic
analysis of RT-PCR for MDR1 using PBGD as control
exhibited coincidence of the logarithmic phase of amplifica-
tion for KB8 cells. This assay is therefore quantitative for
human tumours expressing MDR1 at levels similar to KB8.
We found that pretreatment osteosarcomas express a wide
range of levels of MDR1 expression. Although we have not
shown that the level of expression of MDR1 mRNA is
correlated with response to chemotherapy, it is tempting to
speculate that the high levels of MDR1 expression observed
in some osteosarcomas may be related to outcome. Using the
refined RT-PCR assay we were able to quantitate low to
moderate levels of MDR1 and found that a proportion of
osteosarcomas expressed MDR1 mRNA in this range. It is
possible that moderate levels of MDR1 expression may play
a role in drug resistance in vivo. At present, the patients
enroled in this study are being followed clinically to
determine whether the level of MDR1 mRNA expression
will correlate with disease outcome.
In quantitating the amount of MDR1 mRNA it is
important to understand whether the level of MDR1 is
constant or variable within the tumour. To investigate this
question, MDR1 mRNA was measured in specimens
collected from different sites within the primary tumour for
six cases. MDR1 levels were found to be consistent at various
locations suggesting a relatively homogeneous level of
expression throughout these tumours. However, our results
do not rule out the possibility that cellular heterogeneity
could result in variability ofexpression within subpopulations
of cells. Within each specimen, highly expressing subpopula-
tions ofcells may be diluted with RNA from lower expressing
cells in the RNA extraction technique. Further characterisa-
tion of MDR1 expression by in situ localisation would be a
valuable assay to investigate this possibility, if a sufficiently
sensitive method were available. However, the RT-PCR
assay described above is, to date, the most sensitive method
for quantitation of MDR1 expression in clinical samples.
Combining RT-PCR analysis with immunostaining or in situ
hybridisation localisation assays may offer a greatly improved
insight into the clinical relevance of MDR1.
In vitro studies have shown that MDR1 mRNA levels may
be induced in cancer cells by exposure to various
chemotherapeutic agents (Chaudhary and Roninson, 1993).
Induction of MDR1 mRNA was evaluated in the present
study by determining expression levels before and after the
administration of adjuvant multidrug regimes that invariably
included doxorubicin. In four of 20 cases, the expression
increased substantially, more than doubling. In the remaining
16 cases, the expression either increased somewhat or fell less
than 50% following chemotherapy. These results suggest that
in a minority of osteosarcoma, induction of mRNA may be
increased to the point that resistance becomes a clinical
concern. However, in the majority of cases, levels are not
significantly altered by drug treatment.
Previous studies suggested an association of MDR1
expression with tumour metastasis (Weinstein et al., 1991).
If MDR1 is responsible for resistance leading to recurrence,
MDR1 levels would be expected to increase in later stages
either owing to the selection of MDR1-expressing cells by
chemotherapy, or owing to a change in the phenotype of
tumour cells. Contrary to these expectations, the majority of
cases in this study were found to have relatively constant
levels of MDR1 upon recurrence with metastasis to the lungs.
Many pretreatment tumours exhibited moderate levels of
MDR1 expression suggesting that some osteosarcomas may
be intrinsically drug resistant. Our data indicate that
increased mRNA expression is rarely selected for by
chemotherapy in osteosarcomas and that tumour progres-
sion does not necessarily involve overexpression of MDR1.
In addition, it is possible that mechanisms other than MDR
may play a role in the development of clinical chemoresis-
tance observed in osteosarcomas. Studies on the effects of
MDR1 expression on patient outcome are required to test the
clinical significance of MDR1 expression in osteosarcoma
further and these investigations are in progress.
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